EMEA-001220-PIP01-11-M03

Key facts

Invented name
Olumiant
Active substance
baricitinib
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0157/2018
PIP number
EMEA-001220-PIP01-11-M03
Pharmaceutical form(s)
  • Oral suspension
  • Tablet
Condition(s) / indication(s)
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)
Route(s) of administration
Oral use
Contact for public enquiries
Eli Lilly & Company Limited

Tel. +44 (0)1276 483000
E-mail: eu_paediatric@lilly.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating
Average
1 rating